Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline

(2016) Stefan Sturm et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer’s Dementia and Death: The Cache County Dementia Progression Study

(2015) Matthew E. Peters et al.   AMERICAN JOURNAL OF PSYCHIATRY

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

(2015) Nicola De Stefano et al.   Multiple Sclerosis Journal

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

(2015) Nicola De Stefano et al.   Multiple Sclerosis Journal

The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review

(2014) Barry Reisberg et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

(2014) J Sastre-Garriga et al.   Multiple Sclerosis Journal

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical characterization of RO4602522, a novel, selective and orally active monoamine oxidase type B inhibitor for the treatment of Alzheimer's disease

(2013) Edilio Borroni et al.   Alzheimers & Dementia

Brain MAO-B inhibition in healthy elderly and people with Alzheimer's disease after oral administration of RO4602522

(2013) Benedicte Ricci et al.   Alzheimers & Dementia

Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review

(2012) Dallas P. Seitz et al.   INTERNATIONAL PSYCHOGERIATRICS

Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients

(2012) Maria Zellner et al.   Journal of Proteomics

A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch

(2012) Ivan Berlin et al.   PSYCHOPHARMACOLOGY

Neuropsychiatric symptoms in Alzheimer’s disease

(2011) Constantine G. Lyketsos et al.   Alzheimers & Dementia

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease

(2010) Robert A. Mitchell et al.   CNS Neuroscience & Therapeutics

Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography

(2010) Balázs Gulyás et al.   NEUROCHEMISTRY INTERNATIONAL

Disease progression meta-analysis model in Alzheimer's disease

(2009) Kaori Ito et al.   Alzheimers & Dementia

MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology

(2008) Jyothi K. Mallajosyula et al.   PLoS One